FibroBiologics, Inc.
FBLG
$1.06
-$0.09-7.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.38M | 2.12M | 1.79M | 2.25M | 2.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.03M | 5.07M | 2.59M | 5.04M | 4.49M |
| Operating Income | -4.03M | -5.07M | -2.59M | -5.04M | -4.49M |
| Income Before Tax | -4.12M | -5.00M | -3.24M | -5.78M | -4.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.12M | -5.00M | -3.24M | -5.78M | -4.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.12M | -5.00M | -3.24M | -5.78M | -4.66M |
| EBIT | -4.03M | -5.07M | -2.59M | -5.04M | -4.49M |
| EBITDA | -3.97M | -5.00M | -2.52M | -4.97M | -4.43M |
| EPS Basic | -0.66 | -1.33 | -1.13 | -2.82 | -2.41 |
| Normalized Basic EPS | -0.41 | -0.83 | -0.71 | -1.76 | -1.51 |
| EPS Diluted | -0.66 | -1.33 | -1.13 | -2.82 | -2.41 |
| Normalized Diluted EPS | -0.41 | -0.83 | -0.71 | -1.76 | -1.51 |
| Average Basic Shares Outstanding | 6.27M | 3.77M | 63.19M | 45.23M | 1.93M |
| Average Diluted Shares Outstanding | 6.27M | 3.77M | 63.19M | 45.23M | 1.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |